Systemic Sclerosis: An Update PDF Print E-mail
Friday, 08 March 2013 00:33
Systemic sclerosis (SSc) is a clinically heterogeneous, systemic disorder affecting connective tissue of skin, internal organs, and walls of blood vessels. It is characterized by alterations of the microvasculature in the form of hypoxia, digital ulcers, and pulmonary arterial hypertension; disturbances of the immune system, including dysbalance of cytokine expression, autoantibodies (Auto-ab), and abnormalities of blood progenitor and/or effector cells; and by massive deposition of collagen in the connective tissue of the skin and various internal organs.

This review discusses epidemiology and survival; clinical features including subsets and internal organ involvement; pathophysiology including genetics, microvasculature, immunobiology, fibroblasts (FBs), and connective tissue metabolism; and environmental factors. Early diagnosis and individually tailored therapy help to manage this disorder. Therapy involves immunomodulation and targeting of blood vessels and fibrosis. The multicenter online database “European Scleroderma Trials and Research” project allows further insight of prognostic factors and conception of new therapies. Physical and psychotherapy are important.

To read the full review, click on and download from the link provided below.

 
More articles :

» What is Chelation Therapy?

Chelation (pronounced key-LAY-shun) therapy is a chemical process in which a synthetic solution-EDTA (ethylenediaminetetraacetic acid) is injected into the bloodstream to remove heavy metals and/or minerals from the body. Chelation means "to grab"...

» Scleroderma-Related PAH: The Need for Early Diagnosis and Treatment

Pulmonary arterial hypertension (PAH) associated with scleroderma (systemic sclerosis) is an aggressive disorder with a poor prognosis. Effective therapies are available for PAH but patients with scleroderma-associated PAH have a poorer response to...

» Aspirin, Simvastatin Not Effective for Pulmonary Arterial Hypertension

Neither aspirin nor simvastatin improved outcomes for patients with in a phase II safety and efficacy trial recently published online in and simultaneously presented at the annual meeting of the .The primary end point of 6-minute walk distance did...

» Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and Antioxidants

Systemic sclerosis is a multisystem, connective tissue disease of unknown aetiology characterized by vascular dysfunction, autoimmunity, and enhanced fibroblast activity resulting in fibrosis of the skin, heart, and lungs, and ultimately internal...

» Face Exercises for Scleroderma

Scleroderma is caused by too much collagen in your body, which causes hardening, thickening and tightening of your skin and connective tissues. In localized scleroderma, only your skin is involved; systemic scleroderma damages your inner organs,...

» Skin Autofluorescence Is Not Increased in Patients with Systemic Sclerosis

M. E. Hettema, H. Bootsma, R. Graaff, R. de Vries, C. G. M. Kallenberg, and A. J. SmitReceived 24 May 2011; Accepted 8 August 2011Vascular involvement is a key factor in major manifestations of systemic sclerosis (SSc), such as Raynaud’s...